# Daniele Focosi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1826144/publications.pdf

Version: 2024-02-01

| 204 | 5,438 | 109321 | 102487 |
|---|---|---|---|
| papers | citations | 35 h-index | 66 g-index |

| 233 | 233 | 233 | 7761 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. Journal of Medical Virology, 2022, 94, 491-498. | 5.0 | 17 |
| 2 | Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Review of Vaccines, 2022, 21, 877-884. | 4.4 | 24 |
| 3 | Is SARSâ€CoVâ€2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibodyâ€based therapeutics?. Reviews in Medical Virology, 2022, 32, e2314. | 8.3 | 7 |
| 4 | Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence. Viruses, 2022, 14, 187. | 3.3 | 66 |
| 5 | Convalescent plasma for COVID-19. TSUNAMI is not the final word. European Journal of Internal Medicine, 2022, 97, 116-118. | 2.2 | 4 |
| 6 | Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review. Vaccines, 2022, 10, 94. | 4.4 | 10 |
| 7 | Are convalescent plasma stocks collected during former COVIDâ€19 waves still effective against current <scp>SARSâ€CoV</scp>â€2 variants?. Vox Sanguinis, 2022, 117, 641-646. | 1.5 | 8 |
| 8 | Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine, 2022, 75, 103788. | 6.1 | 149 |
| 9 | A CLUSTER OF SARSâ€COVâ€2 DELTA VARIANT OF CONCERN ADDITIONALLY HARBORING F490S, NORTHERN LOMBARDY, ITALY. International Journal of Infectious Diseases, 2022, 116, 271-272. | 3.3 | 3 |
| 10 | Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. Antiviral Research, 2022, 198, 105247. | 4.1 | 39 |
| 11 | <scp>SARSâ€CoV</scp>â€2 and the safety of blood donations: Time for a brave revision?. Transfusion, 2022, 62, 717-719. | 1.6 | 1 |
| 12 | Convalescent plasma in outpatients with COVID-19. Lancet Respiratory Medicine,the, 2022, 10, 226-228. | 10.7 | 9 |
| 13 | Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 29. | 4.1 | 35 |
| 14 | COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clinical Microbiology Reviews, 2022, 35, e0020021. | 13.6 | 64 |
| 15 | Spike mutations in SARS-CoV-2 AY sublineages of theÂDelta variant of concern: implications for the future of the pandemic. Future Microbiology, 2022, 17, 219-221. | 2.0 | 9 |
| 16 | Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?. Vaccines, 2022, 10, 406. | 4.4 | 2 |
| 17 | Passive immunotherapies for COVIDâ€19: The subtle line between standard and hyperimmune immunoglobulins is getting invisible. Reviews in Medical Virology, 2022, 32, e2341. | 8.3 | 10 |
| 18 | Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert Opinion on Drug Discovery, 2022, 17, 531-546. | 5.0 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Reflections after 2Âyears of COVIDâ€19 pandemic. Reviews in Medical Virology, 2022, 32, e2351. | 8.3 | 1 |
| 20 | <scp>Neutralizing antibody levels against SARSâ€CoV</scp> â€2 <scp>variants of concern Delta and Omicron in vaccine breakthroughâ€infected blood donors</scp>. Transfusion, 2022, , . | 1.6 | 5 |
| 21 | Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics. Life, 2022, 12, 614. | 2.4 | 0 |
| 22 | High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerging Infectious Diseases, 2022, 28, 1083-1083. | 4.3 | 1 |
| 23 | Safety and immunogenicity of synchronous COVID19 and influenza vaccination. Journal of Clinical Virology Plus, 2022, 2, 100082. | 1.0 | 4 |
| 24 | Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19. Virology Journal, 2022, 19, 79. | 3.4 | 5 |
| 25 | Recombination in Coronaviruses, with a Focus on SARS-CoV-2. Viruses, 2022, 14, 1239. | 3.3 | 65 |
| 26 | Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. Viruses, 2022, 14, 1443. | 3.3 | 7 |
| 27 | Monoclonal antibody therapies against SARS-CoV-2. Lancet Infectious Diseases, The, 2022, 22, e311-e326. | 9.1 | 114 |
| 28 | Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases. Journal of Clinical Virology Plus, 2022, 2, 100097. | 1.0 | 6 |
| 29 | What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?. Clinical Microbiology and Infection, 2021, 27, 163-165. | 6.0 | 11 |
| 30 | ABO Blood Group Correlations with Covid-19: Cohort Choice Makes A Difference. Clinical Infectious Diseases, 2021, 72, e919-e919. | 5.8 | 9 |
| 31 | Olfactory and gustatory impairments in COVIDâ€19 patients: Role in early diagnosis and interferences by concomitant drugs. British Journal of Clinical Pharmacology, 2021, 87, 2186-2188. | 2.4 | 2 |
| 32 | ABOâ€incompatible convalescent plasma transfusion: Yes, you can. Transfusion Medicine, 2021, 31, 215-216. | 1.1 | 4 |
| 33 | The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. International Journal of Infectious Diseases, 2021, 102, 244-246. | 3.3 | 9 |
| 34 | Viral infection neutralization tests: A focus on severe acute respiratory syndromeâ€coronavirusâ€2 with implications for convalescent plasma therapy. Reviews in Medical Virology, 2021, 31, e2170. | 8.3 | 45 |
| 35 | The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life, 2021, 11, 144. | 2.4 | 21 |
| 36 | Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes. ERJ Open Research, 2021, 7, 00713-2020. | 2.6 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Neutralising antibody escape of SARSâ€CoVâ€2 spike protein: Risk assessment for antibodyâ€based Covidâ€19 therapeutics and vaccines. Reviews in Medical Virology, 2021, 31, e2231. | 8.3 | 128 |
| 38 | Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naÃ¯ve BNT162b2 vaccine recipients. Vaccine, 2021, 39, 2489-2490. | 3.8 | 11 |
| 39 | Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy. Emerging Infectious Diseases, 2021, 27, 1249-1251. | 4.3 | 47 |
| 40 | COVIDâ€19 convalescent plasma therapy: hit fast, hit hard!. Vox Sanguinis, 2021, 116, 935-942. | 1.5 | 25 |
| 41 | Kinetics of antiâ€SARSâ€COV2 spike protein IgG and IgA antibodies at 4Â°C: Implications for convalescent plasma stability. Transfusion Medicine, 2021, 31, 221-222. | 1.1 | 4 |
| 42 | Clinical predictors of SARSâ€CoVâ€2 neutralizing antibody titers in COVIDâ€19 convalescents: Implications for convalescent plasma donor recruitment. European Journal of Haematology, 2021, 107, 24-28. | 2.2 | 16 |
| 43 | Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin. Life, 2021, 11, 298. | 2.4 | 23 |
| 44 | SARSâ€CoVâ€2 B.1.1.7 reinfection after previous COVIDâ€19 in two immunocompetent Italian patients. Journal of Medical Virology, 2021, 93, 5648-5649. | 5.0 | 11 |
| 45 | Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfusion Clinique Et Biologique, 2021, 28, 132-134. | 0.4 | 14 |
| 46 | Is a single COVID-19 vaccine dose enough in convalescents ?. Human Vaccines and Immunotherapeutics, 2021, 17, 2959-2961. | 3.3 | 10 |
| 47 | COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review. Transfusion and Apheresis Science, 2021, 60, 103071. | 1.0 | 12 |
| 48 | Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody. Journal of Clinical Virology Plus, 2021, 1, 100016. | 1.0 | 5 |
| 49 | SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses, 2021, 13, 1211. | 3.3 | 35 |
| 50 | SYMPTOMATIC SARS-CoV-2 INFECTIONS AFTER FULL SCHEDULE BNT162b2 VACCINATION IN SEROPOSITIVE HEALTHCARE WORKERS: A CASE SERIES FROM A SINGLE INSTITUTION. Emerging Microbes and Infections, 2021, 10, 1-6. | 6.5 | 4 |
| 51 | Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses, 2021, 13, 1514. | 3.3 | 12 |
| 52 | An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opinion on Drug Discovery, 2021, 16, 1403-1414. | 5.0 | 14 |
| 53 | Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donorâ€"recipient differences in concentration of neutralizing antibodies. Clinical Microbiology and Infection, 2021, 27, 987-992. | 6.0 | 6 |
| 54 | Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematology,the, 2021, 8, e593-e604. | 4.6 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | COVID19 immune plasma donation after vaccination: pros and cons.. Transfusion and Apheresis Science, 2021, 60, 103151. | 1.0 | 0 |
| 56 | Molecular validation of pathogenâ€reduction technologies using rollingâ€circle amplification coupled with realâ€time <scp>PCR</scp> for torquetenovirus <scp>DNA</scp> quantification. Transfusion Medicine, 2021, 31, 371-376. | 1.1 | 1 |
| 57 | COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses, 2021, 13, 1594. | 3.3 | 31 |
| 58 | COVID-19 infodemics: the role of mainstream and social media. Clinical Microbiology and Infection, 2021, 27, 1568-1569. | 6.0 | 9 |
| 59 | Introduction of SARSâ€COVâ€2 C.37 (WHO VOI lambda) from Peru to Italy. Journal of Medical Virology, 2021, 93, 6460-6461. | 5.0 | 16 |
| 60 | Lack of neutralizing activity in nonconvalescent sera, regardless of ABO blood group and anti-A isoagglutinin titer. Journal of Clinical Virology Plus, 2021, 1, 100035. | 1.0 | 2 |
| 61 | Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. Diagnostics, 2021, 11, 1663. | 2.6 | 19 |
| 62 | Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19. Emerging Infectious Diseases, 2021, 27, 2728-2731. | 4.3 | 64 |
| 63 | Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy. Emerging Infectious Diseases, 2021, 27, 3180-3182. | 4.3 | 21 |
| 64 | Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. Emerging Microbes and Infections, 2021, 10, 710-712. | 6.5 | 7 |
| 65 | Which Strain Will Finally Become Dominant?. SpringerBriefs in Microbiology, 2021, , 97-99. | 0.1 | 0 |
| 66 | Predicting the Functional Consequences of Mutations. SpringerBriefs in Microbiology, 2021, , 75-75. | 0.1 | 0 |
| 67 | Characterization of SARS-CoV-2 Variants. SpringerBriefs in Microbiology, 2021, , 73-74. | 0.1 | 0 |
| 68 | Whole Genome Mutation Rates. SpringerBriefs in Microbiology, 2021, , 9-10. | 0.1 | 0 |
| 69 | SARS-CoV-2 Variants. SpringerBriefs in Microbiology, 2021, , 55-71. | 0.1 | 0 |
| 70 | Efficacy of Anti-Spike Vaccines and Monoclonal Antibodies Against SARS-CoV-2 Variants. SpringerBriefs in Microbiology, 2021, , 77-91. | 0.1 | 0 |
| 71 | Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy. Emerging Microbes and Infections, 2021, 10, 2010-2015. | 6.5 | 17 |
| 72 | Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing. Annals of Internal Medicine, 2021, 174, 1770-1772. | 3.9 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Urgent Need to Regulate Convalescent Plasma Differently from Thawed Plasma. Transfusion Medicine and Hemotherapy, 2021, 48, 132-133. | 1.6 | 6 |
| 74 | Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. JAMA Network Open, 2021, 4, e2136246. | 5.9 | 50 |
| 75 | Performance Assessment of the LIAISONÂ® SARS-CoV-2 Antigen Assay On Nasopharyngeal Swabs.. New Microbiologica, 2021, 44, . | 0.1 | 0 |
| 76 | Lack of Marseillevirus DNA in immunocompetent and immunocompromised Italian patients. Journal of Medical Virology, 2020, 92, 187-190. | 5.0 | 4 |
| 77 | Convalescent Plasma Therapy for COVID-19: State of the Art. Clinical Microbiology Reviews, 2020, 33, . | 13.6 | 94 |
| 78 | Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs, 2020, 12, 1854149. | 5.2 | 126 |
| 79 | Torque teno virus microRNA detection in cerebrospinal fluids of patients with neurological pathologies. Journal of Clinical Virology, 2020, 133, 104687. | 3.1 | 4 |
| 80 | Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care, 2020, 24, 331. | 5.8 | 39 |
| 81 | Antiâ€A isohaemagglutinin titres and SARSâ€CoVâ€2 neutralization: implications for children and convalescent plasma selection. British Journal of Haematology, 2020, 190, e148-e150. | 2.5 | 42 |
| 82 | The Impact of the COVID-19 â€œInfodemicâ€•on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Safety, 2020, 43, 699-709. | 3.2 | 56 |
| 83 | Assessment of prevalence and load of torquetenovirus viraemia in a large cohort of healthy blood donors. Clinical Microbiology and Infection, 2020, 26, 1406-1410. | 6.0 | 35 |
| 84 | Progressive multifocal leukoencephalopathy and antiâ€CD20 monoclonal antibodies: What do we know after 20 years of rituximab. Reviews in Medical Virology, 2019, 29, e2077. | 8.3 | 74 |
| 85 | Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. Medical Microbiology and Immunology, 2019, 208, 253-258. | 4.8 | 19 |
| 86 | Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?. Annals of Translational Medicine, 2019, 7, S298-S298. | 1.7 | 0 |
| 87 | Torque teno virus monitoring in transplantation: The quest for standardization. American Journal of Transplantation, 2019, 19, 1599-1601. | 4.7 | 12 |
| 88 | Low prevalence of Gemycircularvirus DNA in immunocompetent and immunocompromised subjects. New Microbiologica, 2019, 42, 118-120. | 0.1 | 3 |
| 89 | The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2018, 53, 180-187. | 2.4 | 35 |
| 90 | Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients. Scientific Reports, 2018, 8, 15490. | 3.3 | 59 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside. Cells, 2018, 7, 2. | 4.1 | 30 |
| 92 | Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2018, 90, 1438-1443. | 5.0 | 15 |
| 93 | Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumor Biology, 2017, 39, 101042831769979. | 1.8 | 45 |
| 94 | Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. Journal of Clinical Virology, 2017, 94, 22-28. | 3.1 | 44 |
| 95 | How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?. Current Drug Targets, 2017, 18, 811-825. | 2.1 | 5 |
| 96 | Cyclovirus Vietnam DNA in immunodeficient patients. Journal of Clinical Virology, 2016, 81, 12-15. | 3.1 | 6 |
| 97 | Zika Virus: Implications for Public Health. Clinical Infectious Diseases, 2016, 63, 227-233. | 5.8 | 37 |
| 98 | Torquetenovirus: the human virome from bench to bedside. Clinical Microbiology and Infection, 2016, 22, 589-593. | 6.0 | 172 |
| 99 | Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside. International Reviews of Immunology, 2016, 35, 351-368. | 3.3 | 2 |
| 100 | Effect of Induced Pluripotent Stem Cell Technology in Blood Banking. Stem Cells Translational Medicine, 2016, 5, 269-274. | 3.3 | 9 |
| 101 | Tweaking Mesenchymal Stem/Progenitor Cell Immunomodulatory Properties with Viral Vectors Delivering Cytokines. Stem Cells and Development, 2016, 25, 1321-1341. | 2.1 | 9 |
| 102 | The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 109-130. | 0.1 | 0 |
| 103 | Human Wharton's jellyâ€“derived mesenchymal stromal cells engineered to secrete Epstein-Barr virus interleukin-10 show enhanced immunosuppressive properties. Cytotherapy, 2016, 18, 205-218. | 0.7 | 3 |
| 104 | Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaÏŠVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. Blood, 2016, 128, 1230-1230. | 1.4 | 0 |
| 105 | Lack of usutu virus RNA in cerebrospinal fluid of patients with encephalitis of unknown etiology, Tuscany, Italy. Journal of Medical Virology, 2015, 87, 913-916. | 5.0 | 4 |
| 106 | Short-term kinetics of torque teno virus viraemia after induction immunosuppression confirm T lymphocytes as the main replication-competent cells. Journal of General Virology, 2015, 96, 115-117. | 2.9 | 73 |
| 107 | Cell therapies for treatment of human immunodeficiency virus infection. Reviews in Medical Virology, 2015, 25, 156-174. | 8.3 | 3 |
| 108 | Potential Hurdles to ABO-Incompatible Living Donor Kidney Transplantation Without Augmented Immunosuppression. American Journal of Transplantation, 2015, 15, 1727. | 4.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Acquired factor XIII deficiency after desensitization as a potential contributor to postoperative bleeding: more than meets the eye. Transplant International, 2015, 28, 246-247. | 1.6 | 8 |
| 110 | Getting the most from the Ebola vaccine success. Vaccine, 2015, 33, 7141. | 3.8 | 0 |
| 111 | Estimates of Ebola Virus Case-Fatality Ratio in the 2014 West African Outbreak. Clinical Infectious Diseases, 2015, 60, 829-829. | 5.8 | 4 |
| 112 | Lack of KIs virus DNA in plasma and cerebrospinal fluid in Italy. New Microbiologica, 2015, 38, 593-4. | 0.1 | 1 |
| 113 | Torque Teno Virus Viremia Correlates With Intensity of Maintenance Immunosuppression in Adult Orthotopic Liver Transplant. Journal of Infectious Diseases, 2014, 210, 667-668. | 4.0 | 70 |
| 114 | No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan. Infection, 2014, 42, 1065-1066. | 4.7 | 0 |
| 115 | CDC Crossmatch and C1qSCREEN in Liver Transplantation. Transplantation, 2014, 97, e61. | 1.0 | 0 |
| 116 | Administering 25-hydroxyvitamin D3 in vitamin D-deficient young type 1A diabetic patients reduces reactivity against islet autoantigens. Clinical Nutrition, 2014, 33, 1153-1156. | 5.0 | 18 |
| 117 | Are we overestimating the loss of beta cells in type 2 diabetes?. Diabetologia, 2014, 57, 362-365. | 6.3 | 115 |
| 118 | Endogenous antiâ€C1q antibodies do not interfere with the <scp>C1qScreen</scp>â„¢ assay. Tissue Antigens, 2014, 83, 356-357. | 1.0 | 0 |
| 119 | Induced pluripotent stem cells in hematology: current and future applications. Blood Cancer Journal, 2014, 4, e211-e211. | 6.2 | 21 |
| 120 | Delayed cord clamping. Lancet, The, 2014, 384, 1668. | 13.7 | 0 |
| 121 | ATG Brands and DSA. American Journal of Transplantation, 2014, 14, 737-737. | 4.7 | 1 |
| 122 | Human gyrovirus is not found in human CD34+ hematopoietic stem cells from peripheral blood or umbilical cord. Journal of Clinical Virology, 2013, 57, 182-183. | 3.1 | 3 |
| 123 | Fifth kidney transplantation in a patient with focal segmental glomerulosclerosis. Transplant International, 2013, 26, e19-e21. | 1.6 | 1 |
| 124 | A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4, 502-530. | 1.8 | 152 |
| 125 | Reconstitution Rate of Absolute CD8+ T Lymphocyte Counts Affects Overall Survival After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2012, 34, 29-34. | 0.6 | 11 |
| 126 | Laparoscopic Robot-Assisted Pancreas Transplantation. Transplantation, 2012, 93, 201-206. | 1.0 | 73 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Applications of Laparoscopic Robot-Assisted Surgery to Solid Organ Transplantations. Transplantation, 2012, 94, 695. | 1.0 | 2 |
| 128 | Sustained Improvement of Cardiovascular Risk Factors (CVRF) and Cardiac Function in Type 1 Diabetic (T1D) Patients with Successful Pancreas Transplant Alone (PTA). Transplantation, 2012, 94, 696. | 1.0 | 0 |
| 129 | A Tale of Five Kidneys and One Heart Transplants. Transplantation, 2012, 94, 1080. | 1.0 | 0 |
| 130 | Association of donor-specific microchimerism with graft dysfunction in kidney transplant patients. Transplant Immunology, 2012, 26, 151-155. | 1.2 | 4 |
| 131 | Transplantation of the Pancreas. Current Diabetes Reports, 2012, 12, 568-579. | 4.2 | 31 |
| 132 | Human Gyrovirus DNA in Human Blood, Italy. Emerging Infectious Diseases, 2012, 18, 956-959. | 4.3 | 42 |
| 133 | Xenotropic murine leukaemia virus-related virus is not found in peripheral blood cells from treatment-naive human immunodeficiency virus-positive patients. Clinical Microbiology and Infection, 2012, 18, 184-188. | 6.0 | 8 |
| 134 | Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. Leukemia and Lymphoma, 2011, 52, 142-144. | 1.3 | 2 |
| 135 | The Role of Anti-HLA Antibodies in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1585-1588. | 2.0 | 27 |
| 136 | Cancer transmissibility across HLA barriers between immunocompetent individuals: Rare but not impossible. Human Immunology, 2011, 72, 1-4. | 2.4 | 4 |
| 137 | Organ transplantation after cardiac death. Lancet, The, 2011, 377, 203-204. | 13.7 | 1 |
| 138 | Death of Healthy Volunteers and Professionals on Duty for Cadaveric Graft Shipment. Transplantation, 2011, 91, e79. | 1.0 | 2 |
| 139 | Pretransplant Screening for Donor-Specific Antibodies and Graft Loss. Transplantation, 2011, 92, e15. | 1.0 | 1 |
| 140 | Pancreas rejection after pandemic influenzavirus A(H1N1) vaccination or infection : a report of two cases. Transplant International, 2011, 24, e28-e29. | 1.6 | 24 |
| 141 | Immunosuppressive monoclonal antibodies: current and next generation. Clinical Microbiology and Infection, 2011, 17, 1759-1768. | 6.0 | 17 |
| 142 | Attempt to classify the clinical impact of DNA viruses according to the ability to activate the innate immune system. Journal of Medical Virology, 2011, 83, 1060-1062. | 5.0 | 2 |
| 143 | Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab. Annals of Hematology, 2010, 89, 519-522. | 1.8 | 12 |
| 144 | Areas with high soil percolation by herbicides have higher incidence of low-grade non-Hodgkin lymphomas. Annals of Hematology, 2010, 89, 941-943. | 1.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Concerns on unpredictable pharmacokinetics and pharmacodynamics of natalizumab. Annals of Neurology, 2010, 67, 270-270. | 5.3 | 0 |
| 146 | Improving imatinib delivery to central nervous system. Internal Medicine Journal, 2010, 40, 318-319. | 0.8 | 1 |
| 147 | Progressive Multifocal Leukoencephalopathy: Whatâ€™s New?. Neuroscientist, 2010, 16, 308-323. | 3.5 | 22 |
| 148 | WU and KI Polyomaviruses Remain Orphans in Adults. Journal of Infectious Diseases, 2010, 201, 1276-1276. | 4.0 | 1 |
| 149 | Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy. Oncologist, 2010, 15, 1214-1219. | 3.7 | 51 |
| 150 | Role of Hematopoietic Cells in the Maintenance of Chronic Human Torquetenovirus Plasma Viremia. Journal of Virology, 2010, 84, 6891-6893. | 3.4 | 53 |
| 151 | Bone Marrow Aspiration and Biopsy. New England Journal of Medicine, 2010, 362, 182-183. | 27.0 | 7 |
| 152 | A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. New England Journal of Medicine, 2010, 362, 656-657. | 27.0 | 0 |
| 153 | Prophylactic Platelet Transfusions. New England Journal of Medicine, 2010, 362, 2140-2142. | 27.0 | 1 |
| 154 | Three Paths to Better Tyrosine Kinase Inhibition Behind the Blood-Brain Barrier in Treating Chronic Myelogenous Leukemia and Glioblastoma with Imatinib. Translational Oncology, 2010, 3, 13-15. | 3.7 | 15 |
| 155 | Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. Journal of Clinical Virology, 2010, 47, 189-192. | 3.1 | 92 |
| 156 | Inclusion of rituximab in standard chemotherapy regimens for non-Hodgkin's lymphomas and risk of progressive multifocal leukoencephalopathy.. Journal of Clinical Oncology, 2010, 28, e18541-e18541. | 1.6 | 0 |
| 157 | Lithium and hematology: established and proposed uses. Journal of Leukocyte Biology, 2009, 85, 20-28. | 3.3 | 75 |
| 158 | Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials. Journal of the National Cancer Institute, 2009, 101, 1288-1289. | 6.3 | 8 |
| 159 | Does Contrast Enhancement Predict Survival in Progressive Multifocal Leukoencephalopathy?. Journal of Infectious Diseases, 2009, 199, 1410-1411. | 4.0 | 4 |
| 160 | Lymphotropic Polyomavirus and Progressive Multifocal Leukoencephalopathy. Journal of Clinical Microbiology, 2009, 47, 284-284. | 3.9 | 3 |
| 161 | JC virus DNA in healthy brain tissue: A challenge for progressive multifocal leukoencephalopathy diagnosis. Annals of Neurology, 2009, 65, 230-230. | 5.3 | 3 |
| 162 | Fatal ongoing human cytomegalovirus reactivation during highâ€dose melphalan and autologous stem cell transplantation. Journal of Medical Virology, 2009, 81, 857-860. | 5.0 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: A report in a case of delayed graft failure. Leukemia Research, 2009, 33, 178-181. | 0.8 | 7 |
| 164 | Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: Case report and review of literature. Leukemia Research, 2009, 33, 556-560. | 0.8 | 24 |
| 165 | Hypercytokinemia-induced metabolic encephalopathy in a multiple myeloma patient on hemodialysis undergoing autologous stem cell transplantation: Clinical response after plasma exchange. Transplant Immunology, 2009, 21, 240-243. | 1.2 | 4 |
| 166 | Polyomaviruses other than JCV are not detected in progressive multifocal leukoencephalopathy. Journal of Clinical Virology, 2009, 45, 161-162. | 3.1 | 14 |
| 167 | The role of bone marrow cells for JCV pathogenicity. Journal of Clinical Virology, 2009, 45, 230-231. | 3.1 | 4 |
| 168 | Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncology, The, 2009, 10, 816-824. | 10.7 | 433 |
| 169 | Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 2009, 113, 4834-4840. | 1.4 | 829 |
| 170 | CD57+ T lymphocytes and functional immune deficiency. Journal of Leukocyte Biology, 2009, 87, 107-116. | 3.3 | 217 |
| 171 | a€œBeating the bushesa€• to identify previously unreported cases of a rare and potentially fatal adverse drug reaction: Comparison of HIV-negative rituximab-associated progressive multifocal leucoencephalopathy (PML) cases obtained by the Research on Adverse Drug Events and Report (RADAR), the FDA, the manufacturer, and a literature review. Journal of Clinical Oncology, 2009, 27, 6604-6604. | 1.6 | 0 |
| 172 | Long-term propylthiouracil use and acute myeloid leukemia: A case report and review of the literature. Annals of Hematology, 2008, 87, 233-235. | 1.8 | 5 |
| 173 | Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Annals of Hematology, 2008, 87, 405-412. | 1.8 | 76 |
| 174 | False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma. Annals of Hematology, 2008, 87, 343-344. | 1.8 | 22 |
| 175 | Acute myeloid leukaemia after treatment with <sup>90</sup>Yâ€ibritumomab tiuxetan for follicular lymphoma. Hematological Oncology, 2008, 26, 179-181. | 1.7 | 6 |
| 176 | JC viremia and multiple sclerosis. Journal of NeuroVirology, 2008, 14, 85-86. | 2.1 | 3 |
| 177 | Preemptive valganciclovir for cytomegalovirus infection in hematological patients. Transplant Infectious Disease, 2008, 10, 375-376. | 1.7 | 1 |
| 178 | Ultrasound findings guided a successful hemicolectomy in a leukemic patient with neutropenic enterocolitis. Journal of Ultrasound, 2008, 11, 97-101. | 1.3 | 3 |
| 179 | Sialic acid moieties and 5-HT2a: Two faces of the same receptor for JC virus ?. Journal of Clinical Virology, 2008, 43, 132-133. | 3.1 | 4 |
| 180 | Treatment for elderly patients with multiple myeloma. Lancet, The, 2008, 371, 983-984. | 13.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex. Journal of Leukocyte Biology, 2008, 84, 331-337. | 3.3 | 6 |
| 182 | 5â€HT2aInhibitors for Progressive Multifocal Leukoencephalopathy: Old Drugs for an Old Disease. Journal of Infectious Diseases, 2008, 197, 328-328. | 4.0 | 12 |
| 183 | Smartphone Utilities for Infectious Diseases Specialists. Clinical Infectious Diseases, 2008, 47, 1234-1235. | 5.8 | 7 |
| 184 | Phenobarbital-Associated Bone Marrow Aplasia: A Case Report and Review of the Literature. Acta Haematologica, 2008, 119, 18-21. | 1.4 | 9 |
| 185 | Changes In CD8+57+ T Lymphocyte Expansions After Autologous Hematopoietic Stem Cell Transplantation Correlate With Changes in Torquetenovirus Viremia. Transplantation, 2008, 85, 1867-1868. | 1.0 | 35 |
| 186 | Comment on â€œGerminal Center Helper T Cells Are Dual Functional Regulatory Cells with Suppressive Activity to Conventional CD4+ T Cellsâ€• Journal of Immunology, 2007, 179, 731.1-731. | 0.8 | 1 |
| 187 | CD57 Expression on Lymphoma Microenvironment As a New Prognostic Marker Related to Immune Dysfunction. Journal of Clinical Oncology, 2007, 25, 1289-1291. | 1.6 | 22 |
| 188 | Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases. Haematologica, 2007, 92, e96-e97. | 3.5 | 5 |
| 189 | Risperidone-induced reduction in JC viruria as a surrogate marker for efficacy against progressive multifocal leukoencephalopathy and hemorrhagic cystitis. Journal of Clinical Virology, 2007, 39, 63-64. | 3.1 | 15 |
| 190 | Hypothesis: Central nervous system delivery of cyclosporine A for therapy of progressive multifocal leukoencephalopathy. Journal of Clinical Virology, 2007, 39, 156-158. | 3.1 | 3 |
| 191 | Gliptins. Lancet, The, 2007, 369, 269-270. | 13.7 | 6 |
| 192 | Acute myeloid leukaemia. Lancet, The, 2007, 369, 367. | 13.7 | 5 |
| 193 | Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. Hematological Oncology, 2007, 25, 96-97. | 1.7 | 10 |
| 194 | Hyaluronate and risperidone for hemorrhagic cystitis. Bone Marrow Transplantation, 2007, 39, 57-57. | 2.4 | 8 |
| 195 | Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplantation, 2007, 39, 811-812. | 2.4 | 14 |
| 196 | Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses. Bone Marrow Transplantation, 2007, 40, 1095-1096. | 2.4 | 2 |
| 197 | Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: A clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Research, 2007, 74, 156-158. | 4.1 | 39 |
| 198 | Incubation period of human prion disease. Lancet, The, 2006, 368, 913-914. | 13.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Chaperonin 10 for rheumatoid arthritis. Lancet, The, 2006, 368, 1961. | 13.7 | 1 |
| 200 | Risk in drug trials. Lancet, The, 2006, 368, 2206. | 13.7 | 1 |
| 201 | More on Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation. New England Journal of Medicine, 2006, 355, 212-213. | 27.0 | 3 |
| 202 | An Inactivated Subvirion Influenza A (H5N1) Vaccine. New England Journal of Medicine, 2006, 354, 2724-2725. | 27.0 | 3 |
| 203 | Causes of Chronic Diarrhea. New England Journal of Medicine, 2006, 355, 1833-1834. | 27.0 | 2 |
| 204 | An inactivated subvirion influenza A (H5N1) vaccine. New England Journal of Medicine, 2006, 354, 2724-5; author reply 2724-5. | 27.0 | 1 |